[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"depressive-disorders\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:depressive-disorders":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,8,0,[8,47,89,113,140,178,206,230],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":29,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":46},"100648862","randomized-trial-evaluating-the-effect-of-light-therapy-using-glasses-versus-a-sham-device-on-the-evolution-of-self-reported-depressive-disorders-in-chronic-hemodialysis-patients-100648862",false,"NCT07729358","Evaluation of the Effect of Light Therapy on the Evolution of Self-reported Depressive Disorders in Chronic Hemodialysis Patients","Randomized Trial Evaluating the Effect of Light Therapy Using Glasses Versus a Sham Device on the Evolution of Self-reported Depressive Disorders in Chronic Hemodialysis Patients","LUMIDIAL-2","Inclusion Criteria:\n\n* Patient informed about the nature, process, and objectives of the study and having signed a free and informed consent to participate,\n* Patient treated with conventional hemodialysis for at least 3 months and currently undergoing dialysis 3 times a week,\n* Patient covered by the french national social welfare\n\nNon-Inclusion Criteria:\n\n* Patient who has initiated or modified antidepressive treatment within the 4 weeks prior to the inclusion visit,\n* Patient with initiation of antidepressive treatment within the 10 weeks following the inclusion visit (screening and intervention periods),\n* Patient who has initiated or modified anxiolytic, hypnotic, or melatonin treatment within the 4 weeks prior to the inclusion visit,\n* Patient presenting with binocular blindness or age-related macular degeneration (AMD),\n* Patient receiving medical and\u002For surgical treatment for a retinal condition,\n* Patient who has undergone ocular surgery within the 12 weeks prior to the inclusion visit,\n* Patient scheduled for ocular surgery within the 10 weeks following the inclusion visit (screening and intervention periods),\n* Patient suffering from neurocognitive disorders, schizophrenia or other primary psychotic disorders, or bipolar disorder or related conditions,\n* Pregnant or breastfeeding patient,\n* Patient unable to understand the French language both orally and in writing, making self-assessment impossible,\n* Patient currently participating in another interventional research protocol, except for the IDE-3D protocol (RIPH2) conducted by the CH Annecy Genevois,\n* Patient who has already been randomized in the present study,\n* Patient under guardianship, curatorship, or placed under judicial protection.\n\nRandomisation criteria\n\nThe patient will be considered eligible for randomization if they have a HADS-D screening score dated within a maximum of 15 days and meet one of the following two criteria:\n\n* HADS-D screening score ≥ 8 and \\\u003C 15,\n* HADS-D screening score ≥ 15, provided that a medical follow-up assessment has been conducted following this diagnosis during the screening period, and that it does not lead to the recommendation for the initiation or modification of antidepressant treatment and\u002For psychotherapy within the 10 weeks following the inclusion visit (screening and intervention periods).","ALL","18 Years",{"count":20,"type":21},340,"ESTIMATED","INTERVENTIONAL",[24],"NA","Hemodialysis is an intensive treatment, with a lifestyle dictated by the organization of the dialysis center. This treatment is associated with a decrease in quality of life, an increase in sleep disorders, and depressive disorders.\n\nLight therapy could be a non-pharmacological option for treating depressive states in chronic hemodialysis patients. Indeed, the production of melatonin is stimulated by exposure to light of a defined intensity for 30 minutes in the morning. This hormone influences our sleep-wake cycle. In the general population, light therapy has demonstrated its benefits for depression. This practice could therefore improve sleep quality and mood in chronic hemodialysis patients who experience depressive symptoms.\n\nThe objective of this research is to evaluate the effect of light therapy on the reduction of depressive disorders experienced by chronic hemodialysis patients. Light therapy will be administered using glasses called \"Luminette®,\" three times a week for five weeks, on the days of dialysis sessions in the morning at the center or at home for patients undergoing afternoon dialysis",[27,28],"End-stage Chronic Kidney Disease Treated With Hemodialysis","Depressive Disorders",[30,31,32,33],"Mental health","Light Therapy","Therapeutic and Preventive Strategies","Patient Quality of Life","NOT_YET_RECRUITING","2026-08-13",{"date":37,"type":38},"2026-08-17","ACTUAL",{"date":40,"type":21},"2026-08-15",{"date":42,"type":21},"2028-12-15",{"name":44,"class":45},"Centre Hospitalier Annecy Genevois","OTHER",1,{"id":48,"slug":49,"hasResults":11,"nctId":50,"briefTitle":51,"officialTitle":52,"acronym":4,"eligibilityCriteria":53,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":54,"enrollmentInfo":55,"targetDuration":4,"studyType":22,"phases":57,"briefSummary":58,"conditions":59,"keywords":68,"overallStatus":79,"whyStopped":4,"lastUpdateSubmitDate":80,"lastUpdatePostDateStruct":81,"startDateStruct":83,"completionDateStruct":85,"leadSponsor":87,"locationsCount":46},"100606821","creating-health-course-study-for-people-with-rheumatological-conditions-and-mood-disorders-100606821","NCT07180537","Creating Health Course Study for People With Rheumatological Conditions and Mood Disorders","Transforming Health Habits: Evaluating an Online Wellness Program for Individuals With Rheumatological Conditions and Mood Disorders","Inclusion criteria:\n\n1. A diagnosis of one of the following: Rheumatoid Arthritis (RA), Sjogren's Syndrome, Systemic lupus erythematosus (SLE), Mixed connective tissue disease (MCTD), or Psoriatic Arthritis (PsA), as documented by their treating specialist or primary care provider, as reported by the participant.\n2. Must be age 18 and older, at time of consent.\n3. Must be fluent in both speaking and reading English.\n\n   \\*Study participant must be able to read and comprehend informed consent document and speak with study staff about study document content. Study staff will use discretion in determining whether the study participant can clearly communicate with staff and comprehend the study material during the consent call or prior to the call.\n4. Must have access to high-speed internet with devices capable of audio\u002Fvideo streaming.\n5. Must be willing to participate in an online health course designed to improve dietary intake and self-care routines to help improve cellular function and health, and complete online surveys over the course of a 6-month period.\n6. Individuals must pass the Short Portable Mental Status Questionnaire with scores for normal mental functioning (up to 2 errors). Cognitive impairment as measured by the SPMS Questionnaire could interfere with the completion of the online course.\n\nSCORING\\* 0-2 errors: normal mental functioning 3-4 errors: mild cognitive impairment 5-7 errors: moderate cognitive impairment 8-10 errors: severe cognitive impairment\n\n\\*Allow one more error for a subject with only a grade school education. Allow one less error for a subject with education beyond high school.\n\nSource: Pfeiffer, E. (1975). A short portable mental status questionnaire for the assessment of organic brain deficit in elderly patients. Journal of American Geriatrics Society. 23, 433-41.\n\nExclusion criteria:\n\n1. Inability to provide informed consent, including participation in a consent call conducted via Zoom with the study team during business hours (8:00 a.m. to 5:00 p.m. Central Time (Chicago)).\n2. Participation in another research study investigating an intervention (treatments, medications, diet, or exercise). Participation in observation-only studies are not excluded.\n3. Currently following a modified Paleolithic, low-fat nutrient-dense vegetarian, or Mediterranean diet with 75% OR greater reported compliance.\n4. Any diagnosis or condition that is contraindicated from starting a gentle exercise program (ex. poorly controlled diseases of the heart, kidney, or liver in the prior 12 months, or severe psychiatric disease, e.g., schizophrenia, making adherence to study procedures difficult.","100 Years",{"count":56,"type":21},400,[24],"The goal of this project is to critically evaluate the effectiveness of an online health program designed to improve diet and self-care in patients with rheumatological conditions, including rheumatoid arthritis (RA), Sjogren's syndrome (SS), systemic lupus erythematosus (SLE), mixed connective tissue disease (MCTD), psoriatic arthritis (PsA), anxiety disorders, depressive disorders and moderate depression.\n\nAdditionally, investigators will assess the program's effectiveness, as well as the challenges and facilitators involved in using an online wellness program to reduce fatigue and enhance the quality of life in patients suffering from these conditions.",[60,61,62,63,64,65,28,66,67],"Rheumatoid Arthritis","Sjogren's Syndrome","Systemic Lupus Erythematosus","Mixed Connective Tissue Disease","Psoriatic Arthritis","Anxiety Disorders","Moderate Depression","Moderate Anxiety",[69,70,71,72,73,74,75,76,77,78],"diet","self-care","internet course","anxiety","depression","Sjogren's","rheumatoid arthritis","lupus","fatigue","arthritis","RECRUITING","2026-08-06",{"date":82,"type":38},"2026-08-10",{"date":84,"type":38},"2025-12-01",{"date":86,"type":21},"2027-12-31",{"name":88,"class":45},"Terry L. Wahls",{"id":90,"slug":91,"hasResults":11,"nctId":92,"briefTitle":93,"officialTitle":93,"acronym":94,"eligibilityCriteria":95,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":96,"targetDuration":4,"studyType":22,"phases":98,"briefSummary":99,"conditions":100,"keywords":101,"overallStatus":79,"whyStopped":4,"lastUpdateSubmitDate":104,"lastUpdatePostDateStruct":105,"startDateStruct":107,"completionDateStruct":109,"leadSponsor":111,"locationsCount":112},"100641558","evaluation-of-depression-screening-methods-administered-by-registered-nurses-in-chronic-hemodialysis-patients-100641558","NCT07651436","Evaluation of Depression Screening Methods Administered by Registered Nurses in Chronic Hemodialysis Patients","IDE-3D","Inclusion Criteria:\n\n* Patient informed about the nature, process, and objectives of the study and having signed a free and informed consent to participate,\n* Patient treated with conventional hemodialysis for at least 3 months and currently undergoing dialysis 3 times a week,\n* Patient covered by the french national social welfare\n\nExclusion Criteria:\n\n* Patient suffering from dementia\n* Pregnant or breastfeeding patient\n* Patient unable to understand the French language both orally and in writing, - making self-assessment impossible\n* Patient currently participating in another interventional research protocol or in an exclusion period from such research\n* Patient who has already been included in this study\n* Patient under guardianship, curatorship, or placed under judicial protection.",{"count":97,"type":21},450,[24],"Hemodialysis is a vital replacement therapy for patients with end-stage chronic kidney disease, but it imposes a heavy, demanding, and prolonged management, associated with a significant deterioration in quality of life. Hemodialysis patients are exposed to numerous physical, organizational, and social constraints, including repeated and prolonged sessions at the center, dietary and fluid restrictions, chronic fatigue, and frequent comorbidities. Therefore, depressive disorders in hemodialysis patients represent a major public health issue.\n\nThe literature reports a high prevalence of depressive symptoms among hemodialysis patients, ranging from 22% to 60%, significantly higher than that observed in the general population. These disorders are associated with a significant deterioration in quality of life, increased hospitalizations, lower therapeutic adherence, an increased risk of suicide, and excess mortality. Despite these important clinical consequences, depressive disorders often remain underdiagnosed in hemodialysis.\n\nCurrent guidelines, including those from the Haute Autorité de Santé (HAS), emphasize the importance of regular quality of life assessments in patients with chronic kidney disease and recommend the use of validated questionnaires. However, they do not formalize a specific operational strategy for screening depressive disorders in routine hemodialysis practice, contributing to their under-evaluation.\n\nThe gold standard diagnosis of depressive disorders relies on a structured psychiatric interview, which is difficult to reconcile with the organizational constraints of dialysis centers. Standardized self-assessment tools, such as the Hospital Anxiety and Depression Scale (HADS), particularly its depression subscale (HADS-D), have been widely used. The HADS-D has the advantage of excluding somatic symptoms and has been validated in hemodialysis patients.\n\nHowever, self-assessment relies on the patient's ability to express their subjective experience. Thus, the self-administration of standardized questionnaires in these patients is often challenging due to their age, comorbidities, fatigue, and functional limitations, often necessitating the intervention of healthcare staff. In contrast, registered nurses (IDE) working in hemodialysis possess longitudinal clinical knowledge of patients, acquired over repeated sessions, which can serve as a relevant lever for rapid and standardized screening of depressive symptoms. To date, the diagnostic performance of structured nursing hetero-evaluation remains poorly documented.\n\nThe IDE-3D study aims to evaluate the ability of nurses to identify depressive symptoms in hemodialysis patients using structured tools, comparing the nursing hetero-evaluation of the HADS-D with the self-assessment conducted by the patient. It is part of a pragmatic approach aimed at improving the screening of depressive disorders in hemodialysis, structuring the care pathway, and enhancing the integration of mental health into the overall management of hemodialysis patients.",[28,27],[102,103,30],"Epidemiology","Diagnostic strategies","2026-07-22",{"date":106,"type":38},"2026-07-23",{"date":108,"type":38},"2026-06-26",{"date":110,"type":21},"2028-10",{"name":44,"class":45},2,{"id":114,"slug":115,"hasResults":11,"nctId":116,"briefTitle":117,"officialTitle":118,"acronym":4,"eligibilityCriteria":119,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":120,"targetDuration":4,"studyType":22,"phases":122,"briefSummary":123,"conditions":124,"keywords":125,"overallStatus":79,"whyStopped":4,"lastUpdateSubmitDate":131,"lastUpdatePostDateStruct":132,"startDateStruct":134,"completionDateStruct":136,"leadSponsor":138,"locationsCount":46},"100482975","efficacy-of-a-transdiagnostic-group-treatment-for-emotional-disorders-applied-in-blended-format-a-controlled-study-100482975","NCT05569018","Efficacy of a Transdiagnostic Group Treatment for Emotional Disorders Applied in Blended Format: a Controlled Study.","Efficacy of a Group Treatment Based on Transdiagnostic Perspective for Emotional Disorders and Applied in Blended Format: a Randomized Controlled Trial.","Inclusion Criteria:\n\n* Being 18 years old or more.\n* DSM-5 (APA, 1013) diagnostic criteria for emotional disorder (panic disorder, agoraphobia, social anxiety disorder, generalized anxiety disorder, major depressive disorder, dysthymia, obsessive-compulsive disorder, non-specified anxiety disorder, non-specified depressive disorder).\n* Good understanding of Spanish.\n* Access to the Internet and email address.\n* Informed consent to participate.\n\nExclusion Criteria:\n\n* Diagnosis of a severe mental disorder (psychotic disorder, bipolar disorder, substance and\u002For alcohol dependence).\n* High risk of suicide.\n* Having a serious medical illness or other condition that prevents treatment from being carried out.\n* Receiving another psychological treatment during the study period.\n* Changes and\u002For increases in pharmacological treatment during the study period (a decrease is accepted).",{"count":121,"type":21},144,[24],"This study will consist in a randomized controlled clinical trial (RCT) to test the efficacy of a blended group transversal protocol (BLGr-TP) compared to a face-to-face group transversal protocol (FFGr-TP).\n\nThe main aims of the study are the following:\n\n* To analyze the differential efficacy of the BLGr-TP versus the FFGr-TP for the treatment of emotional disorders in aspects of clinical measures, as well as in terms of retention and dropout rate and adherence.\n* To analyze the differential acceptability of the BLGr-TP versus the FFGr-TP for the treatment of emotional disorders.\n\nIn addition, it is intended to carry out a study of mediators and moderators of the efficacy of both interventions.\n\nThe established hypotheses in relation to the main goals are:\n\n* Both treatment modalities (FFGr-TP and BLGr-TP) will achieve improvements in the symptoms of emotional disorders, reflected in the scores of the clinical measures.\n* The BLGr-TP will show equivalent efficacy to the FFGr-TP.\n* The BLGr-TP will show an acceptability comparable to the face-to-face protocol. Both modalities will be well valued by the participants.\n* In both treatment modalities, the changes achieved are expected to be maintained over time (3, 6 and 12 months).",[65,28],[126,127,128,129,130],"Cognitive-Behavioral Therapy","Transdiagnostic CBT","Blended CBT","Group CBT","Emotional disorders","2026-04-28",{"date":133,"type":38},"2026-05-05",{"date":135,"type":38},"2024-11-23",{"date":137,"type":21},"2027-07",{"name":139,"class":45},"Universitat Jaume I",{"id":141,"slug":142,"hasResults":11,"nctId":143,"briefTitle":144,"officialTitle":145,"acronym":146,"eligibilityCriteria":147,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":148,"enrollmentInfo":149,"targetDuration":4,"studyType":22,"phases":151,"briefSummary":152,"conditions":153,"keywords":160,"overallStatus":79,"whyStopped":4,"lastUpdateSubmitDate":169,"lastUpdatePostDateStruct":170,"startDateStruct":172,"completionDateStruct":174,"leadSponsor":176,"locationsCount":46},"100613187","improving-treatment-for-depression-in-general-practice-using-a-step-by-step-care-plan-100613187","NCT07263321","Improving Treatment for Depression in General Practice Using a Step-by-Step Care Plan.","Optimising Treatment for Patients With Depressive Episodes in General Practice Through Algorithm-Based Treatment: A Randomised, Open-label Controlled Trial.","ODEGA","Inclusion Criteria:\n\n1. The participant must be referred to the study with a diagnosis of unipolar depressive disorder, as judge by the GP.\n2. Severity of the depressive episode corresponding to moderate depression, as judged by the GP.\n3. Clinical uncertainty regarding which of the treatments, medication or psychotherapy, would be the better choice in the case concerned.\n4. Age criteria: Participants must be at least 18 years old and no more than 65 years old at the time of randomisation.\n5. The participant must be a patient in general practice.\n6. Participants must be able to participate in virtual meetings (e.g. by phone or computer) and have e-Boks.\n7. The participant must be willing to receive psychotherapy by a psychologist and\u002For medication.\n8. Must have signed the document of informed consent.\n\nExclusion Criteria:\n\n1. Misuse of substances that might influence the study, as judged by the investigator.\n2. Difficulty in understanding the Danish language, as judged by the investigator.\n3. A diagnosis of dementia.\n4. Medical conditions that might interfere with the study outcome or safety, judged so by the investigator.\n5. Pregnancy.\n6. High risk of non-adherence at the investigator's discretion.\n7. Suicidality: according to C-SSRS with a positive response to question 4 or 5 within the last three months or upon investigator's discretion.\n8. No current medical or psychotherapy treatment initiated within the last 4 weeks prior to screening.","65 Years",{"count":150,"type":21},171,[24],"The goal of this clinical trial is to compare three different treatments for depression in patients with moderate depression in General Practice, aged 18-65 years.\n\nWe wish to investigate the effect of the treatment approaches, and 171 patients will be included in the trial. The participants will be randomised to one of the following three treatments:\n\n1. Standard treatment provided by a general practitioner (i.e. the general practitioner treats the patient as he\u002Fshe would normally do, when treating a patient with depression).\n2. Standard treatment provided by a psychologist in the form behavioural therapy (i.e. the psychologist treats the patient as he\u002Fshe would normally do, when treating a patient with depression).\n3. A step-by-step treatment plan carried out by a general practitioner. The plan includes pre-determined follow-ups and a pre-determined, structured plan for which medications to use and when to increase dose or switch medication.\n\nThe hypothesis is that a structured and step-by-step treatment approach regarding patients with depression, treated in general practice, is more effective than standard treatment provided by a general practitioner and a psychologist.\n\nAll the participants will:\n\n1. Receive one of the three treatments for 12 weeks.\n2. Have meetings with the project staff every 4 weeks (week 0, 4, 8 and 12) were rating scales will be completed, e.g. a rating scale to measure progress or deterioration in the participant's depression.",[154,155,156,28,157,158,159],"Depressive Disorder","Depression - Major Depressive Disorder","Depressive Disorder, Major Depressive Disorder","Depression","Depressive Episodes","Depressive Episode",[161,162,163,164,165,166,167,168],"Treatment for depressive disorder in General Practice","Algorithm-based treatment in General Practice","Algorithm-guided treatment in General Practice","Algorithm-based treatment for depression in General Practice","Algorithm-based treatment for depressive disorder in General Practice","Algorithm-based treatment for depressive episodes in General Practice","Algorithm-guided treatment for depressive episodes in General Practice","Optimising treatment for depressive episodes in general practice","2025-12-04",{"date":171,"type":38},"2025-12-10",{"date":173,"type":21},"2025-12",{"date":175,"type":21},"2027-06",{"name":177,"class":45},"Aalborg University Hospital",{"id":179,"slug":180,"hasResults":11,"nctId":181,"briefTitle":182,"officialTitle":183,"acronym":184,"eligibilityCriteria":185,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":186,"targetDuration":4,"studyType":22,"phases":188,"briefSummary":189,"conditions":190,"keywords":191,"overallStatus":79,"whyStopped":4,"lastUpdateSubmitDate":197,"lastUpdatePostDateStruct":198,"startDateStruct":200,"completionDateStruct":202,"leadSponsor":204,"locationsCount":46},"100605847","study-on-a-digital-ultra-brief-intervention-during-wait-times-for-psychotherapy-100605847","NCT07167849","Study on a Digital Ultra-Brief Intervention During Wait Times for Psychotherapy","Optimizing a Digital Ultra-brief Treatment for Patients Waiting for Face-to-face Psychotherapy: An Investigation of Treatment Content, Human Support, and Patient Expectations (OPTIBRIEF)","OPTIBRIEF","Inclusion Criteria:\n\n* Read the patient information and return signed written informed consent sheet\n* Currently waiting for outpatient psychotherapy (self-report at baseline and assessed per telephone)\n* Age ≥ 18 (self-report at baseline and assessed per telephone)\n* Scoring equal to or above 10 on the PHQ-ADS (self-report at baseline)\n* Fulfilling diagnostic criteria of one or more of the following disorders assessed with the Diagnostic Short-Interview for Mental Disorders (Mini-DIPS, DSM-5 version; Margraf et al., 2017): Major Depressive Disorder, Persistent Depressive Disorder, Social Anxiety Disorder, Panic Disorder, Agoraphobia, Generalized Anxiety Disorder\n* Sufficient German skills (self-report at baseline)\n* Access to the internet (self-report at baseline)\n\nExclusion Criteria:\n\n* Acute suicidality assessed during the telephone interview (Mini-DIPS)\n* Currently taking part in psychotherapy or a scheduled start of psychotherapy prior to the assessment 14 days post-randomization (assessed via self-report and during the DIPS telephone interview)",{"count":187,"type":21},312,[24],"The OPTIBRIEF study investigates different versions of a digital ultra-brief intervention (UKADO - a German acronym for ultra-brief intervention against anxiety and depression online) during the waiting period for psychotherapy. Using a factorial trial design, the components 1) intervention content, 2) human support, and 3) expectation-fostering elements will be examined.\n\nAfter completing initial questionnaires and participating in a diagnostic interview, participants are randomly assigned to one of eight groups and work through a specific version of UKADO. The program can be completed in a session of approximately 60 minutes, after which the exercises should continue to be used. Participants then complete another set of questionnaires at specific time points (after 2 weeks, 5 weeks, 9 weeks, and 24 weeks). A selection of participants also takes part in another telephone appointment to assess experiences with UKADO.\n\nWith the OPTIBRIEF study, the investigators aim to determine which version of the program is most suitable for individuals waiting for a psychotherapy slot. To this end, the investigators examine the effects on anxiety and depression symptom severity, as well as aspects such as participants' experiences with the program.",[28,65],[184,192,193,157,194,195,196],"Ultra-brief treatment","Anxiety","Factorial trial","Wait time","Psychotherapy","2025-11-17",{"date":199,"type":38},"2025-11-18",{"date":201,"type":38},"2025-09-22",{"date":203,"type":21},"2027-12",{"name":205,"class":45},"University of Bern",{"id":207,"slug":208,"hasResults":11,"nctId":209,"briefTitle":210,"officialTitle":211,"acronym":4,"eligibilityCriteria":212,"healthyVolunteers":213,"sex":17,"minAge":214,"maxAge":4,"enrollmentInfo":215,"targetDuration":4,"studyType":217,"phases":4,"briefSummary":218,"conditions":219,"keywords":4,"overallStatus":79,"whyStopped":4,"lastUpdateSubmitDate":221,"lastUpdatePostDateStruct":222,"startDateStruct":224,"completionDateStruct":226,"leadSponsor":228,"locationsCount":46},"100602223","egr2-and-nlrp3-pathways-in-obstructive-sleep-apnea-related-cognitive-and-mood-disorders-100602223","NCT07120711","EGR2 and NLRP3 Pathways in Obstructive Sleep Apnea-Related Cognitive and Mood Disorders","Regulatory Mechanisms of EGR2 and NLRP3 Inflammatory Pathways in Cognitive Impairment and Depressive-Anxiety-Like Behaviors Associated With Obstructive Sleep Apnea-Hypopnea Syndrome","Inclusion Criteria:\n\nChildren aged 2-18 years with obstructive snoring or sleep apnea features on initial ENT outpatient screening.\n\nAdults (\\>18 years) with suspected OSAS in a sleep or respiratory clinic, presenting with chronic snoring, witnessed apneas, or daytime sleepiness, and without severe chronic heart, liver, kidney failure, psychiatric disorders, or pregnancy.\n\nSigned written informed consent by the participant or their legal guardian. Not currently enrolled in any other registered clinical trial.\n\nExclusion Criteria:\n\nPresence of congenital craniofacial malformations. Severe heart, lung, liver, or kidney failure, or major neurological disease. Recent use of anti-inflammatory or other immunomodulatory medications. Current psychiatric disorder or pregnancy",true,"5 Years",{"count":216,"type":21},1000,"OBSERVATIONAL","Obstructive sleep apnea-hypopnea syndrome (OSAS) is a common disorder in which repeated airway blockages during sleep lead to low oxygen levels, inflammation, and disrupted sleep. Many OSAS patients-both children and adults-experience problems with memory, attention, and mood, such as anxiety or depression. However, the exact molecular drivers of these brain changes are not fully understood.\n\nThis observational study will enroll:\n\nChildren (ages 2-18) and adults (\\>18 years) with OSAS, as well as age- and sex-matched healthy volunteers.\n\nClinical assessments: Children will undergo routine ENT examinations (including nasal endoscopy and X-rays); adults will have an overnight sleep study (polysomnography). All participants will complete questionnaires on sleepiness (e.g., ESS), mood (PHQ-9, GAD-7), and cognitive screening (MoCA for adults, age-appropriate scales for children).\n\nSample collection: A small blood draw (3 mL) and, when applicable (e.g., adults undergoing surgery), a tiny subcutaneous fat biopsy. Saliva samples will also be collected.\n\nLaboratory tests:\n\nMeasure expression levels of two key inflammatory pathway genes-EGR2 and NLRP3-in blood cells, saliva, and fat tissue using RNA sequencing, RT-qPCR, and Western Blot.\n\nCorrelate these molecular markers with sleep parameters (AHI, oximetry), cognitive scores, and mood scores.\n\nData analysis: Develop and validate machine-learning models that integrate data from multiple tissues to predict who is at highest risk for cognitive or mood disturbances.",[220,65,28],"Obstructive Sleep Apnea-Hypopnea Syndrome","2025-08-07",{"date":223,"type":38},"2025-08-13",{"date":225,"type":38},"2025-07-01",{"date":227,"type":21},"2026-09-30",{"name":229,"class":45},"Xinhua Hospital, Shanghai Jiao Tong University School of Medicine",{"id":231,"slug":232,"hasResults":11,"nctId":233,"briefTitle":234,"officialTitle":234,"acronym":235,"eligibilityCriteria":236,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":237,"targetDuration":4,"studyType":22,"phases":239,"briefSummary":240,"conditions":241,"keywords":250,"overallStatus":79,"whyStopped":4,"lastUpdateSubmitDate":260,"lastUpdatePostDateStruct":261,"startDateStruct":263,"completionDateStruct":265,"leadSponsor":267,"locationsCount":112},"100576742","co-occurence-of-mental-illness-and-problematic-alcohol-use-an-internet-based-cognitive-behavior-therapy-intervention-100576742","NCT06789250","Co-occurence of Mental Illness and Problematic Alcohol Use: an Internet-based Cognitive Behavior Therapy Intervention","CoMiT","Inclusion Criteria:\n\n* Age ≥18 years\n* AUDIT ≥ 6 points for women and ≥ 8 points for men\n* Symptoms of depression, anxiety disorder and\u002For stress-related illness\n* Adequate ability to speak, read and write Swedish\n* Having access to the internet and a smartphone, computer or other device.\n\nExclusion Criteria:\n\n* Ongoing psychological treatment.\n* Ongoing medication for AUD\n* Recent changes (within the past three months) in psychiatric medication or planned changes during the treatment period. New medication prescribed during the study shall be reported but will not lead to exclusion\n* Severe psychiatric disorders based on a Mini-International Neuropsychiatric Interview (MINI) interview and reported medical history\n* Severe medical conditions that may impede participation in the study\n* Severe cognitive impairment\n* Current suicidality\n* Severe alcohol addiction where specialized treatment is more appropriate\n* Risk for severe alcohol withdrawal symptoms with a need for medical treatment. Participation is possible after completing alcohol withdrawal treatment within the ordinary health-care system, accessible to the Swedish population.\n* Substance use disorder, other than alcohol or nicotine, within the past six months.",{"count":238,"type":21},240,[24],"The goal of this clinical trial is to learn if internet-based cognitive behavior therapy (ICBT ) works to treat co-occurent of problematic alcohol use and mental illness including mild to moderate symptoms of either depression, anxiety, stress or disturbed sleep.\n\nThe main questions the study aims to answer are:\n\n* Does the ICBT program lower the self-rated suffering from mental illness?\n* Does the ICBT program lower the self-reported alcohol intake? Researchers will compare the ICBT program to the participants who are rancomized to a control grout that receives weekly attention from the research team, to see if the treatment works. In both groups, the participants will have the opportunity to ask for support from a therapist during the week days.\n\nParticipants are adults living in Sweden. They will:\n\n* Receive an ICBT program supported by a trained therapist. It consists of modules that the participants will work with on their computer for 10 weeks. Some modules will be compulsory and other optional for the participants.\n* Fill out forms to rate their mental illness and alcohol intake at the start and the end of the study as well as once every week during treatment.\n\nPrimary outcome measures are depression, anxiety and stress symptoms (measured with Depression Anxiety and Stress Scale 21 (DASS-21)) and alcohol intake measured with self-reported amounts. Other, secondary, outcome measures used will for example be about insomnia symptoms and disability assessment. Pre-treatment measurement, post-treatment measurement and 6-months and 12-months follow up is planned to be collected through an online survey.",[242,243,28,244,245,246,247,248,249],"Alcohol Drinking Related Problems","Alcohol Use Disorders","Mental Illness","Mental Stress","Mental and Behavioral Disorders","Sleep Problems","Stress Disorders","Anxiety Disorder\u002FAnxiety State",[251,157,193,252,253,254,255,256,257,258,259],"Internet intervention","Individually tailored","Transdiagnostic","Internet-based cognitive behavioral therapy (ICBT)","Stress","Sleeping disorders","Mental illness","Harmful alcohol use","Alcohol addiction","2025-02-21",{"date":262,"type":38},"2025-02-24",{"date":264,"type":38},"2025-01-05",{"date":266,"type":21},"2026-05",{"name":268,"class":269},"Linkoeping University","OTHER_GOV"]